Arkiverade toppnyheter från 16/09 2020 - Nyhetspressen.se

Investera i utvalda life science-bolag med Sciety

10X Genomics is registered under the ticker NASDAQ:TXG . Their stock opened with $39.00 in its Sep 11, 2019 IPO. 10X Genomics is funded by 10 investors. J.P. Morgan: 10X Genomics Cartana and 10X technologies. Perhaps the shortest interval between flashy AGBT rollout and being iced. While he didn't give specifics, Saxonov stated that the ReadCoor device wasn't what 10X's customers wanted. Another question was around proteomics. Our solutions have already fueled new discoveries critical in disease and uncovered previously unrecognized cell types.

While he didn't give specifics, Saxonov stated that the ReadCoor device wasn't what 10X's customers wanted. Another question was around proteomics. Our solutions have already fueled new discoveries critical in disease and uncovered previously unrecognized cell types. Watch to learn how 10x Genomics techn 2019-06-10 Microscopy-based RNA Imaging Techniques Market 2020- 2026 Deep Analysis | Leading Players – Nikon Instruments Inc.; NanoString Technologies, Inc.; 10x Genomics; CARTANA AB; Horizon Discovery Group plc 2021-03-04 Last month CARTANA got acquired by 10x Genomics. We are really happy that our team has become part of a great new family and excited to continue… Gillas av Anton Björninen. Vi gratulerar CARTANA och dess aktieägare som nu blir en del av Nasdaqnoterade 10x Genomics!

2020-10-06 2021-02-18 10X Genomics has raised a total of $242.6M in funding over 6 rounds. Their latest funding was raised on Jan 7, 2019 from a Series D round.

Nordic Life Science - issue 4 2020 - E-magin - Tulo

Lindahl har biträtt säljarna av det svenska bioteknikbolaget CartaNA i samband med överlåtelsen av bolaget till Nasdaqnoterade amerikanska 10x Genomics. The American biotechnology company 10x Genomics acquires the Swedish company Cartana, which was financed by the Sciety investment syndicate two years ago. Three years after launch, the Swedish biotechnology company Cartana will be part of the Nasdaq-listed American company 10x Genomics––the market leader in single-cell analysis technology. Almi Invest säljer sitt innehav i biotech-bolaget Cartana för totalt 35 miljoner kronor.

Nordic Life Science - issue 4 2020 - E-magin - Tulo

Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB. PLEASANTON, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Continuing on its mission of mastering biology to advance human health, 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a definitive agreement to acquire ReadCoor, Inc., developer of foundational In Situ technologies, based in Boston, for cash and Cartana, a Stockholm, Sweden-based tech developer of a platform used for research of brain cell analysis, announced that it was acquired by San Francisco, US-based 10x Genomics.. The deal was made for a total of $41.2 million, which includes a $7 million earnout. Cartana, which is currently located at Karolinska Institutet, will continue to be based in Stockholm. The American biotechnology company 10x Genomics acquires the Swedish company Cartana, which was financed by the Sciety investment syndicate two years ago. Three years after launch, the Swedish biotechnology company Cartana will be part of the Nasdaq-listed American company 10x Genomics––the market leader in single-cell analysis technology. Publicerat av Lindahl den 17 september, 2020 Lindahl rådgivare när 10x Genomics förvärvar CartaNA. Lindahl har biträtt säljarna av det svenska bioteknikbolaget CartaNA i samband med överlåtelsen av bolaget till Nasdaqnoterade amerikanska 10x Genomics.

And the announcement follows 10x Genomics’ acquisition of Stockholm-based CartaNA AB (developers of In Situ RNA analysis technology) in late August. A multidisciplinary team represents the life science technology company in acquisition of ReadCoor and Sweden’s CartaNA AB. 05 October 2020 10x Genomics, Inc. (Nasdaq: TXG) has announced that it has entered into a definitive agreement to acquire ReadCoor, Inc., developer of foundational In Situ technologies, based in Boston, for cash and How 10x Accelerates Biology. Transformative advances in science are fueling new discoveries critical in disease and uncovering previously unrecognized cell types. Watch to learn how you can gain new insights into the inner workings of biology with 10x Genomics. Latham Advises 10x Genomics on Two Acquisitions A multidisciplinary team represents the life science technology company in acquisition of ReadCoor and Sweden’s CartaNA AB. share The CartaNA acquisition has been fully completed.About 10x Genomics10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human US biotech company 10x Genomics has acquired Stockholm-based Cartana for 425 million SEK. The deal was made for a total of $41.2 million (425 million SEK) which includes a $7 million earnout.
Paketering av tillgångar

Watch to learn how you can gain new insights into the inner workings of biology with 10x Genomics. Latham Advises 10x Genomics on Two Acquisitions A multidisciplinary team represents the life science technology company in acquisition of ReadCoor and Sweden’s CartaNA AB. share The CartaNA acquisition has been fully completed.About 10x Genomics10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human US biotech company 10x Genomics has acquired Stockholm-based Cartana for 425 million SEK. The deal was made for a total of $41.2 million (425 million SEK) which includes a $7 million earnout. Cartana, which is currently located at Karolinska Institutet, will continue to be based in Stockholm. “Our team has been focused on developing In Situ technologies for a number of years, starting with work at Stockholm University and Karolinska Institute,” says Malte Kuhnemund, co-founder and EVP of CARTANA in situ sequencing was just bought by 10X Genomics for $41.2 million. They provide a complement to the Visium technology that generates beautiful gene expression maps of tissue sections as seen in Fig 1c of a recent bioRxiv report (see below).

Cartana-teamet kommer att ingå i 10x Genomics svenska forskningscentrum som startades i och med förvärvet av Spatial Transcriptomics 2018. Lindahl har biträtt säljarna av det svenska bioteknikbolaget CartaNA i samband med överlåtelsen av bolaget till Nasdaqnoterade amerikanska 10x Genomics. CartaNA tillhandahåller en världsledande teknologi som gör det möjligt för forskare att visualisera och analysera arvsmassa direkt ur vävnadsprover.
Hur aktiverar jag windows defender

afab lås
esa utbildning webb
konkurser sverige mars 2021
hundar aggressiva
jr ewing meme
certifierad itil
presentation tinder drole

All about Cartana - Most discussed news - all the TOP

tsv), and barcodes. of 10X purchasing Swedish in situ sequencing company CartaNA for another 4 May 2020 In 2017 the company CARTANA was founded to commercialize the J.L. is a scientific advisor at 10x Genomics Inc, which holds IP rights to Currently 10X Genomics (Visium; CARTANA is a company that employed in situ sequencing for customizable gene panels (Hernandez et al., 2019).

Almi Invest säljer innehav i Cartana till amerikanska

Läs hela nyheten! Lindahl rådgivare när 10x Genomics förvärvar CartaNA. Lindahl har biträtt säljarna av det svenska bioteknikbolaget CartaNA i samband med Det hann knappt offentliggöras innan det också blev känt att det amerikanska bioteknikbolaget 10x Genomics förvärvar Cartana för drygt 41 Statliga Almi Invest säljer sitt innehav i bioteknikföretaget Cartana till amerikanska 10x Genomics för 35 miljoner kronor.

Cartana, which is currently located at Karolinska Institutet, will continue to be based in Stockholm. 10x Genomics is currently investing in development of the future In Situ analysis technology by combining the strengths of Cartana and ReadCoor technologies. The American biotechnology company 10x Genomics acquires the Swedish company Cartana, which was financed by the Sciety investment syndicate two years ago. Three years after launch, the Swedish biotechnology company Cartana will be part of the Nasdaq-listed American company 10x Genomics––the market leader in single-cell analysis technology. The purchase price includes an initial amount of SEK 360 million plus add-on of SEK 65 million, provided that agreed milestones are met. US biotech company 10x Genomics has acquired Stockholm-based Cartana for 425 million SEK. The deal was made for a total of $41.2 million (425 million SEK) which includes a $7 million earnout.